In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

Tolerability Benefits For Infused Form

 
• By Sushmita Panda
  
Multiple Myeloma
Potential New Multiple Myeloma Option Moves Into Phase IIa (Shutterstock)

More from Clinical Trials

More from Therapy Areas